As part of its efforts to address the opioid epidemic, on October 2, 2017, the State of New Jersey issued a proposed rule and summary, and held a public hearing to hear comments from interested parties related to an Act titled Limitations on and Obligations Associated with Prescriber Acceptance of Compensation from Pharmaceutical Manufacturers. QPharma played a key influential role in this process, participating in the hearing as well as providing written remarks.
On December 22, 2017, the Attorney General of New Jersey finalized rules governing prescriber interactions with pharmaceutical manufacturers. As of January 15, 2018, “a prescriber shall not accept more than $10,000 in the aggregate from all pharmaceutical manufacturers in any calendar year for the bona fide services of presentations as speakers at promotional activities, participation on advisory boards, and consulting arrangements. Payments for speaking at education events are not subject to this cap, but must be for fair market value and set forth in a written agreement. Payments for research activities and, consistent with NJ.A.C 13:45J-1.4(a)10, payments for royalties and licensing fees are not subject to this cap.”
In addition to the annual cap, the rule addresses prohibited gifts, payments, and spend limits between pharmaceutical manufacturers and New Jersey physicians. Life sciences companies’ corporate policies should reflect the requirements to ensure compliance. There are various provisions that may require immediate action, including all meals being limited to a total value of $15 for each prescriber; a list of what the prescriber may not at all accept from pharmaceutical manufacturers or manufacturer’s agents, along with a list of what they may accept; and a prescriber serving as a speaker at an educational event must disclose that they have accepted payment for bona fide services from the sponsoring pharmaceutical manufacturer.
QPharma is a leading provider of compliance solutions and services, including physician payments transparency reporting services and consulting. We invite life sciences companies seeking compliance support to contact us today.
About QPharma, Inc.
Founded in 1994, QPharma is the industry leader in cloud-based software and sales for life sciences. The Commercial Services division provides solutions that include sample management and distribution, product launch management, online training, and HCP/KOL targeting and engagement. Services offered by the company’s Professional Services division include validation services, project management, auditing, and training. QPharma is a National Association of Boards of Pharmacy Verified Accredited Wholesale Distributor, and an approved American Medical Association Database Licensee.